Arrowstreet Capital Limited Partnership Sells 73,756 Shares of Fresenius Medical Care AG (NYSE:FMS)

Arrowstreet Capital Limited Partnership trimmed its stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 26.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 205,531 shares of the company's stock after selling 73,756 shares during the quarter. Arrowstreet Capital Limited Partnership's holdings in Fresenius Medical Care were worth $4,653,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in FMS. Smartleaf Asset Management LLC raised its holdings in Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after buying an additional 806 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Fresenius Medical Care during the 3rd quarter valued at $38,000. Jones Financial Companies Lllp lifted its position in shares of Fresenius Medical Care by 80.5% in the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock worth $102,000 after buying an additional 2,012 shares during the last quarter. Venturi Wealth Management LLC boosted its position in Fresenius Medical Care by 8.4% during the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after purchasing an additional 441 shares during the period. Finally, GAMMA Investing LLC lifted its position in Fresenius Medical Care by 43.3% during the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company's stock worth $162,000 after acquiring an additional 2,166 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several research firms have recently issued reports on FMS. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Truist Financial raised their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th.

Fresenius Medical Care Stock Up 0.6 %

Shares of FMS stock traded up $0.14 on Friday, hitting $23.96. 325,143 shares of the stock were exchanged, compared to its average volume of 319,328. The firm has a market capitalization of $14.06 billion, a P/E ratio of 19.80, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. The business has a 50-day moving average of $23.94 and a 200 day moving average of $22.78. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $25.96.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.